View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 12, 2016

Study demonstrates anti-tumour activity evaluation of cancer drug by DiviTum biomarker assay

A new study conducted in the US demonstrated ability of Swedish biotech company Biovica’s DiviTum biomarker assay in testing efficacy of breast cancer drug palbociclib (Ibrance).

A new study conducted in the US demonstrated ability of Swedish biotech company Biovica’s DiviTum biomarker assay in testing efficacy of breast cancer drug palbociclib (Ibrance).

DiviTum measures the activity of the enzyme thymidine kinase (TK) in serum or cell cultures which otherwise is hardly detectable, but in proliferating cells, it increases more than 20-fold in late G1/S-phase.

The TK is hugely dependent on an active cell cycle which consequently makes it a suitable biomarker for cell proliferation.

"These first results correlating DiviTum to palbociclib efficacy are highly promising since there are no other biomarkers available for CDK 4/6 inhibitors today."

Its expression in serum or cell cultures is highly associated with cell proliferation and tumour aggressiveness.

In the biomarker assay, thymidine is replaced by bromodeoxyuridine (BrdU), which is accepted by TK as an analogous substrate.

The TK activity determines the amount of BrdU built into a DNA strand which is then detected using an ELISA technique.

The DiviTum technology operates by amplifying the signal thereby enabling the assay to determine TK activity with high-sensitivity.

The study conducted by Washington University School of Medicine, St Louis, US used the DiviTum assay to measure TK activity in blood samples collected before and after treatment from 50 women with clinical stage II or III estrogen receptor positive, HER2 negative breast cancer who were treated with anastrozole in combination with palbociclib before surgery.

DiviTum assisted in suggesting the anti-proliferative effect of palbociclib which thereby validated the assay as an early indicator of treatment response by CDK 4/6 inhibitors.

Biovica CEO Anders Rylander said: “These first results correlating DiviTum to palbociclib efficacy are highly promising since there are no other biomarkers available for CDK 4/6 inhibitors today.

“We aim to provide DiviTum as a tool for clinicians to optimise the survival and quality-of-life benefits gained by patients treated with this new class of drugs.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network